GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » E10

Regulus Therapeutics (STU:7RG0) E10 : €-75.98 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regulus Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.267. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-75.98 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 51.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Regulus Therapeutics was 51.90% per year. The lowest was 51.90% per year. And the median was 51.90% per year.

As of today (2024-06-04), Regulus Therapeutics's current stock price is €1.98. Regulus Therapeutics's E10 for the quarter that ended in Mar. 2024 was €-75.98. Regulus Therapeutics's Shiller PE Ratio of today is .


Regulus Therapeutics E10 Historical Data

The historical data trend for Regulus Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics E10 Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -579.72 -547.80 -84.33 -75.71

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.60 -77.39 -82.78 -75.71 -75.98

Competitive Comparison of Regulus Therapeutics's E10

For the Biotechnology subindustry, Regulus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Shiller PE Ratio falls into.



Regulus Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regulus Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.267/131.7762*131.7762
=-0.267

Current CPI (Mar. 2024) = 131.7762.

Regulus Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -25.613 100.560 -33.564
201409 -24.211 100.428 -31.768
201412 -45.741 99.070 -60.842
201503 -32.155 99.621 -42.534
201506 -43.837 100.684 -57.374
201509 -26.730 100.392 -35.086
201512 -15.422 99.792 -20.365
201603 -43.104 100.470 -56.535
201606 -42.720 101.688 -55.360
201609 -39.561 101.861 -51.180
201612 -43.229 101.863 -55.924
201703 -42.636 102.862 -54.621
201706 -43.788 103.349 -55.832
201709 -17.703 104.136 -22.402
201712 -14.196 104.011 -17.986
201803 -15.003 105.290 -18.777
201806 -13.610 106.317 -16.869
201809 -10.113 106.507 -12.512
201812 -8.614 105.998 -10.709
201903 -2.744 107.251 -3.371
201906 -2.655 108.070 -3.237
201909 -2.361 108.329 -2.872
201912 -2.070 108.420 -2.516
202003 -2.262 108.902 -2.737
202006 -2.042 108.767 -2.474
202009 -0.340 109.815 -0.408
202012 -0.247 109.897 -0.296
202103 -0.672 111.754 -0.792
202106 -0.647 114.631 -0.744
202109 -0.842 115.734 -0.959
202112 -0.620 117.630 -0.695
202203 -0.418 121.301 -0.454
202206 -0.473 125.017 -0.499
202209 -0.505 125.227 -0.531
202212 -0.378 125.222 -0.398
202303 -0.392 127.348 -0.406
202306 -0.342 128.729 -0.350
202309 -0.375 129.860 -0.381
202312 -0.358 129.419 -0.365
202403 -0.267 131.776 -0.267

Add all the adjusted EPS together and divide 10 will get our e10.


Regulus Therapeutics  (STU:7RG0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Regulus Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (STU:7RG0) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (STU:7RG0) Headlines

No Headlines